Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy
JCO Oncology Practice · 2023-06 · 19 (6) · 331-342
DOI: 10.1200/op.22.00713 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2023-06. Verfasst von Rosalyn I Marar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Hematologic Neoplasms, Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 60 Literaturangaben.
Abstract (Originalsprache)
The field of malignant hematology is transforming with novel immunotherapeutic approaches. Unfortunately, quality of life, treatment efficacy, and life expectancy are negatively affected by cardiotoxic side effects of treatment. To date, the exact mechanism and incidence of cardiotoxicity associated with these therapies is unclear. These events are believed to be triggered or occur concurrently with cytokine release syndrome. Furthermore, there are no formal guidelines to provide evaluation, treatment, and surveillance. We aim to synthesize available literature with updates on the cardiotoxic effects of novel therapies used in malignant hematologic disorders, with a focus on chimeric antigen receptor T-cell therapy and bispecific T-cell engager therapy, along with a proposed algorithm that may guide pretreatment evaluation, monitoring during treatment, and post-treatment surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE.
- Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
- Division of Internal Medicine, University of Iowa Healh Care, Iowa City, IA.
- Division of Hematology-Oncology, Mayo Clinic, Rochester, MN.
ORCID-Profile: Muhannad Aboud Abbasi, Sruti Prathivadhi-Bhayankaram, Hector Villarraga, Vijaya Raj Bhatt, Jonas Paludo
Zitieren
APA
Marar, R. I., Abbasi, M. A., Prathivadhi-Bhayankaram, S., Daryanani, A., Villarraga, H., Anavekar, N., Bhatt, V. R., & Paludo, J. (2023). Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy. JCO Oncology Practice, 19(6), 331-342. https://doi.org/10.1200/op.22.00713
Vancouver
Marar RI, Abbasi MA, Prathivadhi-Bhayankaram S, Daryanani A, Villarraga H, Anavekar N, et al. Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy. JCO Oncology Practice. 2023;19(6):331-342. doi:10.1200/op.22.00713
BibTeX
@article{Marar2023,
author = {Marar, Rosalyn I and Abbasi, Muhannad Aboud and Prathivadhi-Bhayankaram, Sruti and Daryanani, Andres and Villarraga, Hector and Anavekar, Nandan and Bhatt, Vijaya Raj and Paludo, Jonas},
title = {Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy},
journal = {JCO Oncology Practice},
year = {2023},
volume = {19},
number = {6},
pages = {331--342},
doi = {10.1200/op.22.00713}
}
EUVIMED